Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31575822 | 0.85 | GRIN2D (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31711442 | 0.85 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9126903 | 0.84 | TDP1 (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL18745020 | 0.82 | GRIN2D (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL18225530 | 0.82 | PKM (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30168968 | 0.80 | TDP1 (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL345622 | 0.80 | TDP1 (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL18745017 | 0.80 | GRIN2D (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28892545 | 0.80 | GRIN2D (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30829772 | 0.80 | GRIN2D (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087650-A1 | VINYLOXY-ARYL COMPOUNDS FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2026-04-30 | — | — | WO | disclosed |
| CN-113117376-B | Phenanthroline derivative extracting agent and preparation method and application thereof | 中国科学院高能物理研究所 | 2022-08-19 | — | — | CN | disclosed |
| CN-113117376-A | Phenanthroline-derived extracting agent and preparation method and application thereof | 中国科学院高能物理研究所 | 2021-07-16 | — | — | CN | disclosed |
| EP-3508484-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| CN-108774214-B | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3342771-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| EP-3375780-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| CN-106928203-B | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-8709129-B2 | Compounds useful as ligands of actinides, their synthesis and their uses | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-04-29 | — | — | US | disclosed |
| EP-2694501-A1 | 2,9-DIPYRIDYL-1,10-PHENANTHROLINE DERIVATIVES USEFUL AS ACTINIDE LIGANDS, METHOD FOR SYNTHESIZING SAME, AND USES THEREOF | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2014-02-12 | — | — | EP | disclosed |
| US-20140030172-A1 | 2,9-DIPYRIDYL-1,10-PHENANTHROLINE DERIVATIVES USEFUL AS ACTINIDE LIGANDS, METHOD FOR SYNTHESIZING SAME, AND USES THEREOF | UNIVERSITE DE NANTES (FR) | 2014-01-30 | — | — | US | disclosed |
| EP-2456766-B1 | COMPOUNDS SUITABLE FOR USE AS ACTINIDE LIGANDS, SYNTHESIS AND USES THEREOF | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2013-11-06 | — | — | EP | disclosed |
| WO-2012130902-A1 | 2,9-DIPYRIDYL-1,10-PHENANTHROLINE DERIVATIVES USEFUL AS ACTINIDE LIGANDS, METHOD FOR SYNTHESIZING SAME, AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-10-04 | — | — | WO | disclosed |
| US-20120186396-A1 | COMPOUNDS USEFUL AS LIGANDS OF ACTINIDES, THEIR SYNTHESIS AND THEIR USES | UNIVERSITE DE NANTES (FR) | 2012-07-26 | — | — | US | disclosed |
| EP-2456766-A1 | COMPOUNDS SUITABLE FOR USE AS ACTINIDE LIGANDS, SYNTHESIS AND USES THEREOF | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011009814-A1 | COMPOUNDS SUITABLE FOR USE AS ACTINIDE LIGANDS, SYNTHESIS AND USES THEREOF | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2011-01-27 | — | — | WO | disclosed |
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-13 | — | — | US | disclosed |
| US-6794395-B1 | Substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120186396-A1 | COMPOUNDS USEFUL AS LIGANDS OF ACTINIDES, THEIR SYNTHESIS AND THEIR USES | AHR, ARNT, HRH3 | GRIN2D 4574/4885GRIN3B 4228/4885GRIN1 4642/4885 |
| US-20140030172-A1 | 2,9-DIPYRIDYL-1,10-PHENANTHROLINE DERIVATIVES USEFUL AS ACTINIDE LIGANDS, METHOD FOR SYNTHESIZING SAME, AND USES THEREOF | NRP1, AHR, NR0B1 | GRIN2D 2626/4885GRIN3B 2333/4885GRIN1 1743/4885 |
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | CCNE1, CDK1, CCNI | GRIN2D 1489/4885GRIN3B 1915/4885GRIN1 756/4885 |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | GRIN2D 2639/4885GRIN3B 1964/4885GRIN1 1848/4885 |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | GRIN2D 2639/4885GRIN3B 1964/4885GRIN1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.